Supplementing NAD+ via Olaparib treatment alleviated the reduction of ENaCα abundance raised by NDUFS1 deficiency, improved AFC, and suppressed the progression of ALI. The gene discussed is NDUFS1; the disease is acute respiratory distress syndrome.